Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics Ltd. stock.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company that regularly publishes updates on its dual business model: development of inflammation and immunology (I&I) biologics and operation of a boutique biologics CDMO under the Scinai Bioservices brand. The news flow around SCNI reflects both scientific progress and the evolution of its contract development and manufacturing activities.
Company press releases highlight several recurring themes. On the R&D side, Scinai reports advances in its NanoAb-based I&I pipeline, including anti‑IL‑17 programs for psoriasis and additional NanoAbs arising from collaborations with the Max Planck Society and University Medical Center Göttingen. News items also cover the PC111 program, a first‑in‑class human anti-Fas Ligand monoclonal antibody being developed for severe dermatological conditions such as pemphigus vulgaris and SJS/TEN through an option agreement to acquire Pincell Srl.
On the CDMO side, Scinai’s news frequently addresses growth in Scinai Bioservices, including revenue contributions from its U.S. subsidiary, new service orders, and infrastructure expansions such as an Israel Innovation Authority grant to fund an advanced sterile fill‑and‑finish system. These updates provide context on how the company is expanding its role as a boutique CDMO serving early-stage biotech clients in Israel, the United States, and Europe.
Investors and industry observers can also find announcements on equity financing arrangements, grant applications and outcomes, participation in sector conferences, and governance or cost-structure changes reported via Form 6‑K. This news page aggregates those releases so readers can follow SCNI’s financial results, pipeline milestones, CDMO capacity developments, and strategic transactions over time.
Scinai Immunotherapeutics (NASDAQ: SCNI) announced a webinar scheduled for May 7th, 2025, at 11:30 AM EST to discuss PC111, a novel monoclonal antibody targeting soluble Fas ligand (sFasL) for treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). The webinar follows Scinai's March 27th binding option agreement to acquire Italian biotech Pincell srl.
The company's Polish subsidiary has submitted a €12 million grant application under the European Funds for Modern Economy program, with a decision expected in Q3 2025. The webinar will feature key executives and medical experts who will discuss the diseases, current treatments, and PC111's development plan.
Scinai Immunotherapeutics (Nasdaq: SCNI) has entered a binding option agreement to acquire Italian biotech company Pincell srl. The acquisition centers around PC111, a monoclonal antibody in development for treating severe dermatological conditions including Pemphigus, Steven Johnson's Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN).
Key developments include:
- PC111 has received Orphan Drug Designation in Pemphigus from the European Medicines Agency
- Plans to file for FDA Orphan Drug and Breakthrough Designation for both Pemphigus and SJS/TEN
- Scinai's Polish subsidiary has submitted a €12 million grant application under the European Funds for Modern Economy program
- Grant decision expected by mid-July/beginning of August 2025
Scinai Immunotherapeutics (NASDAQ: SCNI) has announced its participation in the BIO-Europe Spring 2025 conference in Milan, Italy, from March 17-19. The company's leadership team, including CEO Amir Reichman, CTO Dr. Dalit Weinstein-Fischer, and Business Development Director Solomon Gahtan, will engage with various stakeholders.
The company will focus on three main objectives: showcasing their inflammation and immunology (I&I) product pipeline to potential pharma partners interested in co-development or licensing of NanoAbs, presenting their end-to-end biologics CDMO services, and meeting with institutional and private investors. Interested parties can schedule meetings through the conference partnering platform or by emailing bd@scinai.com. Scinai will maintain presence at exhibitor booth #22 throughout the conference.
Scinai Immunotherapeutics (Nasdaq: SCNI) has secured a $10 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global's fund YA II PN, The three-year agreement allows Scinai to sell American Depository Shares (ADSs) at its discretion, with each ADS representing 4,000 ordinary shares.
The purchase price will be set at a 3% discount to the lowest daily volume-weighted average price over three consecutive trading days. Key features include:
- No obligation to utilize the facility
- 9.99% beneficial ownership cap
- No minimum commitments or penalties
- No restrictions on other capital-raising activities
The company plans to use potential proceeds for developing NanoAbs programs, supporting its CDMO business, and general corporate purposes including R&D, regulatory matters, and capital investments.
Scinai Immunotherapeutics (Nasdaq: SCNI), a biopharmaceutical company focused on inflammation and immunology products and CDMO services, has announced its leadership's participation in three major US healthcare conferences in January 2025. CEO Amir Reichman and Board Chairman Mark Germain will attend the IATI Mini Mixiii Conference in Miami (Jan 9), the JP Morgan HealthCare Conference in San Francisco (Jan 13-15), and the SIC Biotech Symposium in San Francisco (Jan 14).
During these events, they will meet with institutional and private investors, potential pharma partners interested in their NanoAbs technology, and prospective CDMO services clients. Interested parties can schedule meetings through the conference platforms or by contacting ir@scinai.com. The company has also released a video showcasing their 2024 achievements.
Scinai Immunotherapeutics (Nasdaq: SCNI) has established a U.S. subsidiary, Scinai Bioservices Inc., for its Contract Development and Manufacturing Services (CDMO) business unit. The company's Jerusalem facility includes 20,000 square feet of clean rooms and laboratories operating under cGMP conditions, compliant with EMA and FDA requirements.
Since launching in 2024, the CDMO unit has executed drug development projects for nine biotech companies, including process development, scale-up, and drug manufacturing services. The U.S. expansion aims to capitalize on growing demand for biological early-stage drug development services, particularly amid capacity constraints and the BIOSECURE Act's restrictions on foreign biotech companies. The company has already secured its first U.S. customer, Serpin Pharma, for clinical manufacturing support.
Scinai Immunotherapeutics (Nasdaq: SCNI) has appointed Prof. Michael Schön to its Scientific Advisory Board. Prof. Schön is currently the Director of Dermatology, Venereology, and Allergology at the University Medical Center Göttingen and serves as Vice Dean and Deputy Director for Research and Teaching. He brings extensive expertise in dermatology and immunology, with over 440 scientific publications and significant experience in treating inflammatory skin diseases.
Prof. Schön expressed enthusiasm about contributing to Scinai's innovative pipeline, particularly in addressing unmet medical needs in chronic inflammatory skin diseases. The company's CEO, Amir Reichman, highlighted Prof. Schön's expertise in psoriasis and atopic dermatitis as valuable assets for advancing Scinai's inflammation and immunology biological products pipeline.
Scinai Immunotherapeutics (Nasdaq: SCNI) has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board. Dr. Sadeh, former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, brings over 20 years of experience in drug development and clinical research. He will focus on advancing Scinai's lead IL-17 program and VHH antibody pipeline. At BMS, he led multiple drug approvals, including Sotyktu for psoriasis. Dr. Sadeh previously held senior positions at Sanofi, AstraZeneca, and Schering-Plough, and earned his MD from Mount Sinai School of Medicine and M.Sc. from Harvard Medical School.
Scinai Immunotherapeutics (NASDAQ: SCNI) reported financial results for the nine months ended September 30, 2024. The company's shareholders' equity improved to positive $10 million from negative $7.3 million, primarily due to the conversion of a EUR 26.6 million EIB loan into preferred shares. Revenue reached $452,000, compared to no revenues in the same period of 2023. The company reported a net gain of $7,026,000 versus a net loss of $4,170,000 in the previous year. Cash position decreased to $1,169,000 from $5,010,000. The CDMO business unit received work orders valued at approximately $600,000 and expects material revenue growth in coming years.